Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCCLillian L. Siu, Jérôme Fayette, Caroline Even et al.|JAMA Oncology|2018Cited by 315
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Helena Rebelo‐de‐Andrade, Michael S. Hwang et al.|Clinical Cancer Research|2025Cited by 26
A Multicenter Evaluation of Different Chemotherapy Regimens in Older Adults With Head and Neck Squamous Cell Carcinoma Undergoing Definitive ChemoradiationAlexander Rühle, Nils H. Nicolay, M. Weymann et al.|International Journal of Radiation Oncology*Biology*Physics|2023Cited by 16
Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumabXuefeng Wang, Christine H. Chung, Tingyi Li et al.|Cancer Immunology Immunotherapy|2025Cited by 10
Predicting cisplatin tolerability in older adults with head and neck cancer – Insights for improved chemoradiation outcomesAlexander Rühle, Nils H. Nicolay, M. Weymann et al.|Radiotherapy and Oncology|2024Cited by 5